#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=CYP2A6 genetic variation alters striatal-cingulate circuits, network hubs and executive processing in smokers Background Variation in the CYP2A6 gene alters the rate of nicotine metabolic inactivation and is associated with smoking behaviors and cessation success rates.
1-1	0-6	CYP2A6	_
1-2	7-14	genetic	_
1-3	15-24	variation	_
1-4	25-31	alters	_
1-5	32-50	striatal-cingulate	_
1-6	51-59	circuits	_
1-7	60-61	,	_
1-8	62-69	network	_
1-9	70-74	hubs	_
1-10	75-78	and	_
1-11	79-88	executive	_
1-12	89-99	processing	_
1-13	100-102	in	_
1-14	103-110	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
1-15	111-121	Background	_
1-16	122-131	Variation	_
1-17	132-134	in	_
1-18	135-138	the	_
1-19	139-145	CYP2A6	_
1-20	146-150	gene	_
1-21	151-157	alters	_
1-22	158-161	the	_
1-23	162-166	rate	_
1-24	167-169	of	_
1-25	170-178	nicotine	_
1-26	179-188	metabolic	_
1-27	189-201	inactivation	_
1-28	202-205	and	_
1-29	206-208	is	_
1-30	209-219	associated	_
1-31	220-224	with	_
1-32	225-232	smoking	_
1-33	233-242	behaviors	_
1-34	243-246	and	_
1-35	247-256	cessation	_
1-36	257-264	success	_
1-37	265-270	rates	_
1-38	271-272	.	_

Text=The underlying neurobiological mechanisms of this genetic influence remain unknown.
2-1	273-276	The	_
2-2	277-287	underlying	_
2-3	288-303	neurobiological	_
2-4	304-314	mechanisms	_
2-5	315-317	of	_
2-6	318-322	this	_
2-7	323-330	genetic	_
2-8	331-340	influence	_
2-9	341-347	remain	_
2-10	348-355	unknown	_
2-11	356-357	.	_

Text=Methods Intrinsic functional connectivity strength (FCS), a whole brain, data driven, graph theory based method, was applied to resting state fMRI data in 66 smokers and 92 nonsmokers.
3-1	358-365	Methods	_
3-2	366-375	Intrinsic	_
3-3	376-386	functional	_
3-4	387-399	connectivity	_
3-5	400-408	strength	_
3-6	409-410	(	_
3-7	411-414	FCS	_
3-8	415-416	)	_
3-9	417-418	,	_
3-10	419-420	a	_
3-11	421-426	whole	_
3-12	427-432	brain	_
3-13	433-434	,	_
3-14	435-439	data	_
3-15	440-446	driven	_
3-16	447-448	,	_
3-17	449-454	graph	_
3-18	455-461	theory	_
3-19	462-467	based	_
3-20	468-474	method	_
3-21	475-476	,	_
3-22	477-480	was	_
3-23	481-488	applied	_
3-24	489-491	to	_
3-25	492-499	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
3-26	500-505	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
3-27	506-510	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
3-28	511-515	data	_
3-29	516-518	in	_
3-30	519-521	66	_
3-31	522-529	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
3-32	530-533	and	_
3-33	534-536	92	_
3-34	537-547	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
3-35	548-549	.	_

Text=A subset of subjects (n=23/20; smokers/nonsmokers) performed the Monetary Incentive Delay (MID) task, probing reward anticipation and a Go/NoGo task, probing response inhibition, on two occasions, in the presence and absence of a nicotine patch.
4-1	550-551	A	_
4-2	552-558	subset	_
4-3	559-561	of	_
4-4	562-570	subjects	_
4-5	571-572	(	_
4-6	573-580	n=23/20	_
4-7	581-582	;	_
4-8	583-601	smokers/nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
4-9	602-603	)	_
4-10	604-613	performed	_
4-11	614-617	the	_
4-12	618-626	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
4-13	627-636	Incentive	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
4-14	637-642	Delay	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
4-15	643-644	(	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
4-16	645-648	MID	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
4-17	649-650	)	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
4-18	651-655	task	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
4-19	656-657	,	_
4-20	658-665	probing	_
4-21	666-672	reward	_
4-22	673-685	anticipation	_
4-23	686-689	and	_
4-24	690-691	a	_
4-25	692-699	Go/NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
4-26	700-704	task	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
4-27	705-706	,	_
4-28	707-714	probing	_
4-29	715-723	response	_
4-30	724-734	inhibition	_
4-31	735-736	,	_
4-32	737-739	on	_
4-33	740-743	two	_
4-34	744-753	occasions	_
4-35	754-755	,	_
4-36	756-758	in	_
4-37	759-762	the	_
4-38	763-771	presence	_
4-39	772-775	and	_
4-40	776-783	absence	_
4-41	784-786	of	_
4-42	787-788	a	_
4-43	789-797	nicotine	_
4-44	798-803	patch	_
4-45	804-805	.	_

Text=Results A significant CYP2A6 genotype × Smoking effect was found in the dorsal anterior cingulate cortex (dACC) and ventral striatum (VS), such that the normal (vs. slow) genotype individuals showed greater FCS in smokers but not nonsmokers.
5-1	806-813	Results	_
5-2	814-815	A	_
5-3	816-827	significant	_
5-4	828-834	CYP2A6	_
5-5	835-843	genotype	_
5-6	844-845	×	_
5-7	846-853	Smoking	_
5-8	854-860	effect	_
5-9	861-864	was	_
5-10	865-870	found	_
5-11	871-873	in	_
5-12	874-877	the	_
5-13	878-884	dorsal	_
5-14	885-893	anterior	_
5-15	894-903	cingulate	_
5-16	904-910	cortex	_
5-17	911-912	(	_
5-18	913-917	dACC	_
5-19	918-919	)	_
5-20	920-923	and	_
5-21	924-931	ventral	_
5-22	932-940	striatum	_
5-23	941-942	(	_
5-24	943-945	VS	_
5-25	946-947	)	_
5-26	948-949	,	_
5-27	950-954	such	_
5-28	955-959	that	_
5-29	960-963	the	_
5-30	964-970	normal	_
5-31	971-972	(	_
5-32	973-976	vs.	_
5-33	977-981	slow	_
5-34	982-983	)	_
5-35	984-992	genotype	_
5-36	993-1004	individuals	_
5-37	1005-1011	showed	_
5-38	1012-1019	greater	_
5-39	1020-1023	FCS	_
5-40	1024-1026	in	_
5-41	1027-1034	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
5-42	1035-1038	but	_
5-43	1039-1042	not	_
5-44	1043-1053	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
5-45	1054-1055	.	_

Text=FCS was negatively associated with nicotine dependence severity in slow metabolizers.
6-1	1056-1059	FCS	_
6-2	1060-1063	was	_
6-3	1064-1074	negatively	_
6-4	1075-1085	associated	_
6-5	1086-1090	with	_
6-6	1091-1099	nicotine	_
6-7	1100-1110	dependence	_
6-8	1111-1119	severity	_
6-9	1120-1122	in	_
6-10	1123-1127	slow	_
6-11	1128-1140	metabolizers	_
6-12	1141-1142	.	_

Text=Both hubs were biased by inputs from the insula identified from seed-based connectivity.
7-1	1143-1147	Both	_
7-2	1148-1152	hubs	_
7-3	1153-1157	were	_
7-4	1158-1164	biased	_
7-5	1165-1167	by	_
7-6	1168-1174	inputs	_
7-7	1175-1179	from	_
7-8	1180-1183	the	_
7-9	1184-1190	insula	_
7-10	1191-1201	identified	_
7-11	1202-1206	from	_
7-12	1207-1217	seed-based	_
7-13	1218-1230	connectivity	_
7-14	1231-1232	.	_

Text=Similar Gene × Environment interactions were seen in VS during smoking abstinence when subjects performed the MID task and in dACC when they performed the Go/NoGo task; both reductions were “ normalized ” in smokers (and increased in nonsmokers) following acute nicotine administration.
8-1	1233-1240	Similar	_
8-2	1241-1245	Gene	_
8-3	1246-1247	×	_
8-4	1248-1259	Environment	_
8-5	1260-1272	interactions	_
8-6	1273-1277	were	_
8-7	1278-1282	seen	_
8-8	1283-1285	in	_
8-9	1286-1288	VS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
8-10	1289-1295	during	_
8-11	1296-1303	smoking	_
8-12	1304-1314	abstinence	_
8-13	1315-1319	when	_
8-14	1320-1328	subjects	_
8-15	1329-1338	performed	_
8-16	1339-1342	the	_
8-17	1343-1346	MID	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
8-18	1347-1351	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
8-19	1352-1355	and	_
8-20	1356-1358	in	_
8-21	1359-1363	dACC	_
8-22	1364-1368	when	_
8-23	1369-1373	they	_
8-24	1374-1383	performed	_
8-25	1384-1387	the	_
8-26	1388-1395	Go/NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
8-27	1396-1400	task	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
8-28	1401-1402	;	_
8-29	1403-1407	both	_
8-30	1408-1418	reductions	_
8-31	1419-1423	were	_
8-32	1424-1425	“	_
8-33	1426-1436	normalized	_
8-34	1437-1438	”	_
8-35	1439-1441	in	_
8-36	1442-1449	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
8-37	1450-1451	(	_
8-38	1452-1455	and	_
8-39	1456-1465	increased	_
8-40	1466-1468	in	_
8-41	1469-1479	nonsmokers	_
8-42	1480-1481	)	_
8-43	1482-1491	following	_
8-44	1492-1497	acute	_
8-45	1498-1506	nicotine	_
8-46	1507-1521	administration	_
8-47	1522-1523	.	_

Text=Conclusions Since the CYP2A6 effect was seen only in smokers, these data suggest that the rate of nicotine metabolism, and thus the concentration of nicotine presented to brain over the course of nicotine addiction, shapes brain circuits that, among other functions, compute reward and impulsivity processes.
9-1	1524-1535	Conclusions	_
9-2	1536-1541	Since	_
9-3	1542-1545	the	_
9-4	1546-1552	CYP2A6	_
9-5	1553-1559	effect	_
9-6	1560-1563	was	_
9-7	1564-1568	seen	_
9-8	1569-1573	only	_
9-9	1574-1576	in	_
9-10	1577-1584	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
9-11	1585-1586	,	_
9-12	1587-1592	these	_
9-13	1593-1597	data	_
9-14	1598-1605	suggest	_
9-15	1606-1610	that	_
9-16	1611-1614	the	_
9-17	1615-1619	rate	_
9-18	1620-1622	of	_
9-19	1623-1631	nicotine	_
9-20	1632-1642	metabolism	_
9-21	1643-1644	,	_
9-22	1645-1648	and	_
9-23	1649-1653	thus	_
9-24	1654-1657	the	_
9-25	1658-1671	concentration	_
9-26	1672-1674	of	_
9-27	1675-1683	nicotine	_
9-28	1684-1693	presented	_
9-29	1694-1696	to	_
9-30	1697-1702	brain	_
9-31	1703-1707	over	_
9-32	1708-1711	the	_
9-33	1712-1718	course	_
9-34	1719-1721	of	_
9-35	1722-1730	nicotine	_
9-36	1731-1740	addiction	_
9-37	1741-1742	,	_
9-38	1743-1749	shapes	_
9-39	1750-1755	brain	_
9-40	1756-1764	circuits	_
9-41	1765-1769	that	_
9-42	1770-1771	,	_
9-43	1772-1777	among	_
9-44	1778-1783	other	_
9-45	1784-1793	functions	_
9-46	1794-1795	,	_
9-47	1796-1803	compute	_
9-48	1804-1810	reward	_
9-49	1811-1814	and	_
9-50	1815-1826	impulsivity	_
9-51	1827-1836	processes	_
9-52	1837-1838	.	_

Text=Methods and Materials Participants Resting state BOLD fMRI data were acquired from non-treatment seeking smokers (n=66) and nonsmokers (n=92), matched by age, sex, IQ and race (Table 1).
10-1	1839-1846	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1847-1850	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1851-1860	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1861-1873	Participants	_
10-5	1874-1881	Resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-6	1882-1887	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-7	1888-1892	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-8	1893-1897	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-9	1898-1902	data	_
10-10	1903-1907	were	_
10-11	1908-1916	acquired	_
10-12	1917-1921	from	_
10-13	1922-1935	non-treatment	_
10-14	1936-1943	seeking	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale
10-15	1944-1951	smokers	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale
10-16	1952-1953	(	_
10-17	1954-1958	n=66	_
10-18	1959-1960	)	_
10-19	1961-1964	and	_
10-20	1965-1975	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
10-21	1976-1977	(	_
10-22	1978-1982	n=92	_
10-23	1983-1984	)	_
10-24	1985-1986	,	_
10-25	1987-1994	matched	_
10-26	1995-1997	by	_
10-27	1998-2001	age	_
10-28	2002-2003	,	_
10-29	2004-2007	sex	_
10-30	2008-2009	,	_
10-31	2010-2012	IQ	_
10-32	2013-2016	and	_
10-33	2017-2021	race	_
10-34	2022-2023	(	_
10-35	2024-2029	Table	_
10-36	2030-2031	1	_
10-37	2032-2033	)	_
10-38	2034-2035	.	_

Text=Subjects were selected from a large cohort of individuals who gave written informed consent under protocols approved by the NIDA-IRP IRB.
11-1	2036-2044	Subjects	_
11-2	2045-2049	were	_
11-3	2050-2058	selected	_
11-4	2059-2063	from	_
11-5	2064-2065	a	_
11-6	2066-2071	large	_
11-7	2072-2078	cohort	_
11-8	2079-2081	of	_
11-9	2082-2093	individuals	_
11-10	2094-2097	who	_
11-11	2098-2102	gave	_
11-12	2103-2110	written	_
11-13	2111-2119	informed	_
11-14	2120-2127	consent	_
11-15	2128-2133	under	_
11-16	2134-2143	protocols	_
11-17	2144-2152	approved	_
11-18	2153-2155	by	_
11-19	2156-2159	the	_
11-20	2160-2168	NIDA-IRP	_
11-21	2169-2172	IRB	_
11-22	2173-2174	.	_

Text=IRB approval for CYP2A6 genotyping was granted at the University of Toronto.
12-1	2175-2178	IRB	_
12-2	2179-2187	approval	_
12-3	2188-2191	for	_
12-4	2192-2198	CYP2A6	_
12-5	2199-2209	genotyping	_
12-6	2210-2213	was	_
12-7	2214-2221	granted	_
12-8	2222-2224	at	_
12-9	2225-2228	the	_
12-10	2229-2239	University	_
12-11	2240-2242	of	_
12-12	2243-2250	Toronto	_
12-13	2251-2252	.	_

Text=A subset of smokers (n=23; 15 normal and 8 reduced metabolizers) and nonsmokers (n=20; 9 normal and 11 reduced) also performed two fMRI tasks following resting BOLD data acquisition: the Monetary Incentive Delay (MID) task, which assesses neuronal activity during anticipation of and outcome for monetary rewards, and a Go/NoGo task assessing response inhibition.
13-1	2253-2254	A	_
13-2	2255-2261	subset	_
13-3	2262-2264	of	_
13-4	2265-2272	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
13-5	2273-2274	(	_
13-6	2275-2279	n=23	_
13-7	2280-2281	;	_
13-8	2282-2284	15	_
13-9	2285-2291	normal	_
13-10	2292-2295	and	_
13-11	2296-2297	8	_
13-12	2298-2305	reduced	_
13-13	2306-2318	metabolizers	_
13-14	2319-2320	)	_
13-15	2321-2324	and	_
13-16	2325-2335	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
13-17	2336-2337	(	_
13-18	2338-2342	n=20	_
13-19	2343-2344	;	_
13-20	2345-2346	9	_
13-21	2347-2353	normal	_
13-22	2354-2357	and	_
13-23	2358-2360	11	_
13-24	2361-2368	reduced	_
13-25	2369-2370	)	_
13-26	2371-2375	also	_
13-27	2376-2385	performed	_
13-28	2386-2389	two	_
13-29	2390-2394	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
13-30	2395-2400	tasks	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
13-31	2401-2410	following	_
13-32	2411-2418	resting	_
13-33	2419-2423	BOLD	_
13-34	2424-2428	data	_
13-35	2429-2440	acquisition	_
13-36	2441-2442	:	_
13-37	2443-2446	the	_
13-38	2447-2455	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
13-39	2456-2465	Incentive	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
13-40	2466-2471	Delay	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
13-41	2472-2473	(	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
13-42	2474-2477	MID	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
13-43	2478-2479	)	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
13-44	2480-2484	task	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
13-45	2485-2486	,	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
13-46	2487-2492	which	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
13-47	2493-2501	assesses	_
13-48	2502-2510	neuronal	_
13-49	2511-2519	activity	_
13-50	2520-2526	during	_
13-51	2527-2539	anticipation	_
13-52	2540-2542	of	_
13-53	2543-2546	and	_
13-54	2547-2554	outcome	_
13-55	2555-2558	for	_
13-56	2559-2567	monetary	_
13-57	2568-2575	rewards	_
13-58	2576-2577	,	_
13-59	2578-2581	and	_
13-60	2582-2583	a	_
13-61	2584-2591	Go/NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
13-62	2592-2596	task	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
13-63	2597-2606	assessing	_
13-64	2607-2615	response	_
13-65	2616-2626	inhibition	_
13-66	2627-2628	.	_

Text=See SI for details of fMRI data acquisition and preprocessing and voxel-based morphometry (VBM) data analyses and results.
14-1	2629-2632	See	_
14-2	2633-2635	SI	_
14-3	2636-2639	for	_
14-4	2640-2647	details	_
14-5	2648-2650	of	_
14-6	2651-2655	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
14-7	2656-2660	data	_
14-8	2661-2672	acquisition	_
14-9	2673-2676	and	_
14-10	2677-2690	preprocessing	_
14-11	2691-2694	and	_
14-12	2695-2706	voxel-based	_
14-13	2707-2718	morphometry	_
14-14	2719-2720	(	_
14-15	2721-2724	VBM	_
14-16	2725-2726	)	_
14-17	2727-2731	data	_
14-18	2732-2740	analyses	_
14-19	2741-2744	and	_
14-20	2745-2752	results	_
14-21	2753-2754	.	_

Text=Genotyping Genomic DNA was extracted from blood samples and genotyped for CYP2A6 as described.
15-1	2755-2765	Genotyping	_
15-2	2766-2773	Genomic	_
15-3	2774-2777	DNA	_
15-4	2778-2781	was	_
15-5	2782-2791	extracted	_
15-6	2792-2796	from	_
15-7	2797-2802	blood	_
15-8	2803-2810	samples	_
15-9	2811-2814	and	_
15-10	2815-2824	genotyped	_
15-11	2825-2828	for	_
15-12	2829-2835	CYP2A6	_
15-13	2836-2838	as	_
15-14	2839-2848	described	_
15-15	2849-2850	.	_

Text=Based on the impact of enzymatic activity, subjects were grouped into normal, intermediate and slow metabolizers.
16-1	2851-2856	Based	_
16-2	2857-2859	on	_
16-3	2860-2863	the	_
16-4	2864-2870	impact	_
16-5	2871-2873	of	_
16-6	2874-2883	enzymatic	_
16-7	2884-2892	activity	_
16-8	2893-2894	,	_
16-9	2895-2903	subjects	_
16-10	2904-2908	were	_
16-11	2909-2916	grouped	_
16-12	2917-2921	into	_
16-13	2922-2928	normal	_
16-14	2929-2930	,	_
16-15	2931-2943	intermediate	_
16-16	2944-2947	and	_
16-17	2948-2952	slow	_
16-18	2953-2965	metabolizers	_
16-19	2966-2967	.	_

Text=Due to the more limited cohort size available for task data, we combined the slow and intermediate genotype groups into a single reduced genotype group for task analysis.
17-1	2968-2971	Due	_
17-2	2972-2974	to	_
17-3	2975-2978	the	_
17-4	2979-2983	more	_
17-5	2984-2991	limited	_
17-6	2992-2998	cohort	_
17-7	2999-3003	size	_
17-8	3004-3013	available	_
17-9	3014-3017	for	_
17-10	3018-3022	task	_
17-11	3023-3027	data	_
17-12	3028-3029	,	_
17-13	3030-3032	we	_
17-14	3033-3041	combined	_
17-15	3042-3045	the	_
17-16	3046-3050	slow	_
17-17	3051-3054	and	_
17-18	3055-3067	intermediate	_
17-19	3068-3076	genotype	_
17-20	3077-3083	groups	_
17-21	3084-3088	into	_
17-22	3089-3090	a	_
17-23	3091-3097	single	_
17-24	3098-3105	reduced	_
17-25	3106-3114	genotype	_
17-26	3115-3120	group	_
17-27	3121-3124	for	_
17-28	3125-3129	task	_
17-29	3130-3138	analysis	_
17-30	3139-3140	.	_

Text=FCS analysis FCS, defined as the sum of functional connectivity between any one voxel and all other brain voxels, was computed for each subject from 6 min of BOLD fMRI acquired with subjects ’ eyes open.
18-1	3141-3144	FCS	_
18-2	3145-3153	analysis	_
18-3	3154-3157	FCS	_
18-4	3158-3159	,	_
18-5	3160-3167	defined	_
18-6	3168-3170	as	_
18-7	3171-3174	the	_
18-8	3175-3178	sum	_
18-9	3179-3181	of	_
18-10	3182-3192	functional	_
18-11	3193-3205	connectivity	_
18-12	3206-3213	between	_
18-13	3214-3217	any	_
18-14	3218-3221	one	_
18-15	3222-3227	voxel	_
18-16	3228-3231	and	_
18-17	3232-3235	all	_
18-18	3236-3241	other	_
18-19	3242-3247	brain	_
18-20	3248-3254	voxels	_
18-21	3255-3256	,	_
18-22	3257-3260	was	_
18-23	3261-3269	computed	_
18-24	3270-3273	for	_
18-25	3274-3278	each	_
18-26	3279-3286	subject	_
18-27	3287-3291	from	_
18-28	3292-3293	6	_
18-29	3294-3297	min	_
18-30	3298-3300	of	_
18-31	3301-3305	BOLD	_
18-32	3306-3310	fMRI	_
18-33	3311-3319	acquired	_
18-34	3320-3324	with	_
18-35	3325-3333	subjects	_
18-36	3334-3335	’	_
18-37	3336-3340	eyes	_
18-38	3341-3345	open	_
18-39	3346-3347	.	_

Text=Functional connectivity between voxels was measured using Pearson correlation in MATLAB (The MathWorks Inc, Natick, Massachusetts).
19-1	3348-3358	Functional	_
19-2	3359-3371	connectivity	_
19-3	3372-3379	between	_
19-4	3380-3386	voxels	_
19-5	3387-3390	was	_
19-6	3391-3399	measured	_
19-7	3400-3405	using	_
19-8	3406-3413	Pearson	_
19-9	3414-3425	correlation	_
19-10	3426-3428	in	_
19-11	3429-3435	MATLAB	_
19-12	3436-3437	(	_
19-13	3438-3441	The	_
19-14	3442-3451	MathWorks	_
19-15	3452-3455	Inc	_
19-16	3456-3457	,	_
19-17	3458-3464	Natick	_
19-18	3465-3466	,	_
19-19	3467-3480	Massachusetts	_
19-20	3481-3482	)	_
19-21	3483-3484	.	_

Text=FCS was computed after thresholding the correlation map at r> 0.25.
20-1	3485-3488	FCS	_
20-2	3489-3492	was	_
20-3	3493-3501	computed	_
20-4	3502-3507	after	_
20-5	3508-3520	thresholding	_
20-6	3521-3524	the	_
20-7	3525-3536	correlation	_
20-8	3537-3540	map	_
20-9	3541-3543	at	_
20-10	3544-3545	r	_
20-11	3546-3547	>	_
20-12	3548-3552	0.25	_
20-13	3553-3554	.	_

Text=A voxel-wise threshold of P <0.01 and a spatial-extent of 30 contiguous voxels were determined via Monte Carlo simulation to provide a corrected threshold of P <0.05.
21-1	3555-3556	A	_
21-2	3557-3567	voxel-wise	_
21-3	3568-3577	threshold	_
21-4	3578-3580	of	_
21-5	3581-3582	P	_
21-6	3583-3584	<	_
21-7	3585-3589	0.01	_
21-8	3590-3593	and	_
21-9	3594-3595	a	_
21-10	3596-3610	spatial-extent	_
21-11	3611-3613	of	_
21-12	3614-3616	30	_
21-13	3617-3627	contiguous	_
21-14	3628-3634	voxels	_
21-15	3635-3639	were	_
21-16	3640-3650	determined	_
21-17	3651-3654	via	_
21-18	3655-3660	Monte	_
21-19	3661-3666	Carlo	_
21-20	3667-3677	simulation	_
21-21	3678-3680	to	_
21-22	3681-3688	provide	_
21-23	3689-3690	a	_
21-24	3691-3700	corrected	_
21-25	3701-3710	threshold	_
21-26	3711-3713	of	_
21-27	3714-3715	P	_
21-28	3716-3717	<	_
21-29	3718-3722	0.05	_
21-30	3723-3724	.	_

Text=MID and Go/NoGo tasks Subjects performed two tasks on two occasions, separated by 1–7 days.
22-1	3725-3728	MID	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
22-2	3729-3732	and	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
22-3	3733-3740	Go/NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
22-4	3741-3746	tasks	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
22-5	3747-3755	Subjects	_
22-6	3756-3765	performed	_
22-7	3766-3769	two	_
22-8	3770-3775	tasks	_
22-9	3776-3778	on	_
22-10	3779-3782	two	_
22-11	3783-3792	occasions	_
22-12	3793-3794	,	_
22-13	3795-3804	separated	_
22-14	3805-3807	by	_
22-15	3808-3811	1–7	_
22-16	3812-3816	days	_
22-17	3817-3818	.	_

Text=A nicotine or placebo patch was placed, in random order, 2–9 hours prior to scanning.
23-1	3819-3820	A	_
23-2	3821-3829	nicotine	_
23-3	3830-3832	or	_
23-4	3833-3840	placebo	_
23-5	3841-3846	patch	_
23-6	3847-3850	was	_
23-7	3851-3857	placed	_
23-8	3858-3859	,	_
23-9	3860-3862	in	_
23-10	3863-3869	random	_
23-11	3870-3875	order	_
23-12	3876-3877	,	_
23-13	3878-3881	2–9	_
23-14	3882-3887	hours	_
23-15	3888-3893	prior	_
23-16	3894-3896	to	_
23-17	3897-3905	scanning	_
23-18	3906-3907	.	_

Text=Trials in the MID task included four sequential stimuli: PRIME-1 (gain, loss or neutral), PRIME-2 (win/loss magnitude), TARGET, and FEEDBACK; a button press was required to the TARGET.
24-1	3908-3914	Trials	_
24-2	3915-3917	in	_
24-3	3918-3921	the	_
24-4	3922-3925	MID	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-5	3926-3930	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-6	3931-3939	included	_
24-7	3940-3944	four	_
24-8	3945-3955	sequential	_
24-9	3956-3963	stimuli	_
24-10	3964-3965	:	_
24-11	3966-3973	PRIME-1	_
24-12	3974-3975	(	_
24-13	3976-3980	gain	_
24-14	3981-3982	,	_
24-15	3983-3987	loss	_
24-16	3988-3990	or	_
24-17	3991-3998	neutral	_
24-18	3999-4000	)	_
24-19	4001-4002	,	_
24-20	4003-4010	PRIME-2	_
24-21	4011-4012	(	_
24-22	4013-4021	win/loss	_
24-23	4022-4031	magnitude	_
24-24	4032-4033	)	_
24-25	4034-4035	,	_
24-26	4036-4042	TARGET	_
24-27	4043-4044	,	_
24-28	4045-4048	and	_
24-29	4049-4057	FEEDBACK	_
24-30	4058-4059	;	_
24-31	4060-4061	a	_
24-32	4062-4068	button	_
24-33	4069-4074	press	_
24-34	4075-4078	was	_
24-35	4079-4087	required	_
24-36	4088-4090	to	_
24-37	4091-4094	the	_
24-38	4095-4101	TARGET	_
24-39	4102-4103	.	_

Text=For the Go/NoGo task, subjects viewed a serial stream of alternating ‘ X ’ and ‘ Y ’ letters and were to respond to each target while the stimulus was present on the screen.
25-1	4104-4107	For	_
25-2	4108-4111	the	_
25-3	4112-4119	Go/NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
25-4	4120-4124	task	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
25-5	4125-4126	,	_
25-6	4127-4135	subjects	_
25-7	4136-4142	viewed	_
25-8	4143-4144	a	_
25-9	4145-4151	serial	_
25-10	4152-4158	stream	_
25-11	4159-4161	of	_
25-12	4162-4173	alternating	_
25-13	4174-4175	‘	_
25-14	4176-4177	X	_
25-15	4178-4179	’	_
25-16	4180-4183	and	_
25-17	4184-4185	‘	_
25-18	4186-4187	Y	_
25-19	4188-4189	’	_
25-20	4190-4197	letters	_
25-21	4198-4201	and	_
25-22	4202-4206	were	_
25-23	4207-4209	to	_
25-24	4210-4217	respond	_
25-25	4218-4220	to	_
25-26	4221-4225	each	_
25-27	4226-4232	target	_
25-28	4233-4238	while	_
25-29	4239-4242	the	_
25-30	4243-4251	stimulus	_
25-31	4252-4255	was	_
25-32	4256-4263	present	_
25-33	4264-4266	on	_
25-34	4267-4270	the	_
25-35	4271-4277	screen	_
25-36	4278-4279	.	_

Text=NoGo stimuli, in which the target stimuli did not alternate (e.g.
26-1	4280-4284	NoGo	_
26-2	4285-4292	stimuli	_
26-3	4293-4294	,	_
26-4	4295-4297	in	_
26-5	4298-4303	which	_
26-6	4304-4307	the	_
26-7	4308-4314	target	_
26-8	4315-4322	stimuli	_
26-9	4323-4326	did	_
26-10	4327-4330	not	_
26-11	4331-4340	alternate	_
26-12	4341-4342	(	_
26-13	4343-4346	e.g	_
26-14	4347-4348	.	_

Text=X, X), required response inhibition.
27-1	4349-4350	X	_
27-2	4351-4352	,	_
27-3	4353-4354	X	_
27-4	4355-4356	)	_
27-5	4357-4358	,	_
27-6	4359-4367	required	_
27-7	4368-4376	response	_
27-8	4377-4387	inhibition	_
27-9	4388-4389	.	_

Text=Since we had strong a priori interest in the ventral striatum (VS) for the MID task and dorsal anterior cingulate cortex (dACC) for the Go/NoGo task, we did region of interest analysis and small volume correction (Pcorrected <0.05) using respectively, a striatal atlas (http: //fsl.fmrib.ox.ac.uk/fsl) and dACC mask.
28-1	4390-4395	Since	_
28-2	4396-4398	we	_
28-3	4399-4402	had	_
28-4	4403-4409	strong	_
28-5	4410-4411	a	_
28-6	4412-4418	priori	_
28-7	4419-4427	interest	_
28-8	4428-4430	in	_
28-9	4431-4434	the	_
28-10	4435-4442	ventral	_
28-11	4443-4451	striatum	_
28-12	4452-4453	(	_
28-13	4454-4456	VS	_
28-14	4457-4458	)	_
28-15	4459-4462	for	_
28-16	4463-4466	the	_
28-17	4467-4470	MID	_
28-18	4471-4475	task	_
28-19	4476-4479	and	_
28-20	4480-4486	dorsal	_
28-21	4487-4495	anterior	_
28-22	4496-4505	cingulate	_
28-23	4506-4512	cortex	_
28-24	4513-4514	(	_
28-25	4515-4519	dACC	_
28-26	4520-4521	)	_
28-27	4522-4525	for	_
28-28	4526-4529	the	_
28-29	4530-4537	Go/NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
28-30	4538-4542	task	_
28-31	4543-4544	,	_
28-32	4545-4547	we	_
28-33	4548-4551	did	_
28-34	4552-4558	region	_
28-35	4559-4561	of	_
28-36	4562-4570	interest	_
28-37	4571-4579	analysis	_
28-38	4580-4583	and	_
28-39	4584-4589	small	_
28-40	4590-4596	volume	_
28-41	4597-4607	correction	_
28-42	4608-4609	(	_
28-43	4610-4620	Pcorrected	_
28-44	4621-4622	<	_
28-45	4623-4627	0.05	_
28-46	4628-4629	)	_
28-47	4630-4635	using	_
28-48	4636-4648	respectively	_
28-49	4649-4650	,	_
28-50	4651-4652	a	_
28-51	4653-4661	striatal	_
28-52	4662-4667	atlas	_
28-53	4668-4669	(	_
28-54	4670-4674	http	_
28-55	4675-4676	:	_
28-56	4677-4701	//fsl.fmrib.ox.ac.uk/fsl	_
28-57	4702-4703	)	_
28-58	4704-4707	and	_
28-59	4708-4712	dACC	_
28-60	4713-4717	mask	_
28-61	4718-4719	.	_

Text=Statistical analysis A 3 (Genotype) × 2 (Smokers, Nonsmokers) ANCOVA was performed on whole brain FCS maps, using age, gender, IQ, race and years of education as covariates.
29-1	4720-4731	Statistical	_
29-2	4732-4740	analysis	_
29-3	4741-4742	A	_
29-4	4743-4744	3	_
29-5	4745-4746	(	_
29-6	4747-4755	Genotype	_
29-7	4756-4757	)	_
29-8	4758-4759	×	_
29-9	4760-4761	2	_
29-10	4762-4763	(	_
29-11	4764-4771	Smokers	_
29-12	4772-4773	,	_
29-13	4774-4784	Nonsmokers	_
29-14	4785-4786	)	_
29-15	4787-4793	ANCOVA	_
29-16	4794-4797	was	_
29-17	4798-4807	performed	_
29-18	4808-4810	on	_
29-19	4811-4816	whole	_
29-20	4817-4822	brain	_
29-21	4823-4826	FCS	_
29-22	4827-4831	maps	_
29-23	4832-4833	,	_
29-24	4834-4839	using	_
29-25	4840-4843	age	_
29-26	4844-4845	,	_
29-27	4846-4852	gender	_
29-28	4853-4854	,	_
29-29	4855-4857	IQ	_
29-30	4858-4859	,	_
29-31	4860-4864	race	_
29-32	4865-4868	and	_
29-33	4869-4874	years	_
29-34	4875-4877	of	_
29-35	4878-4887	education	_
29-36	4888-4890	as	_
29-37	4891-4901	covariates	_
29-38	4902-4903	.	_

Text=Post-hoc one-way ANOVA and two-tailed independent t-tests identified differences between groups.
30-1	4904-4912	Post-hoc	_
30-2	4913-4920	one-way	_
30-3	4921-4926	ANOVA	_
30-4	4927-4930	and	_
30-5	4931-4941	two-tailed	_
30-6	4942-4953	independent	_
30-7	4954-4961	t-tests	_
30-8	4962-4972	identified	_
30-9	4973-4984	differences	_
30-10	4985-4992	between	_
30-11	4993-4999	groups	_
30-12	5000-5001	.	_

Text=MID and Go/NoGo tasks were analyzed using GLM.
31-1	5002-5005	MID	_
31-2	5006-5009	and	_
31-3	5010-5017	Go/NoGo	_
31-4	5018-5023	tasks	_
31-5	5024-5028	were	_
31-6	5029-5037	analyzed	_
31-7	5038-5043	using	_
31-8	5044-5047	GLM	_
31-9	5048-5049	.	_

Text=Associations between FCS in regions showing significant GENOTYPE × SMOKING interactions and FTND/CPD were tested using Pearson ’ s correlation analyses.
32-1	5050-5062	Associations	_
32-2	5063-5070	between	_
32-3	5071-5074	FCS	_
32-4	5075-5077	in	_
32-5	5078-5085	regions	_
32-6	5086-5093	showing	_
32-7	5094-5105	significant	_
32-8	5106-5114	GENOTYPE	_
32-9	5115-5116	×	_
32-10	5117-5124	SMOKING	_
32-11	5125-5137	interactions	_
32-12	5138-5141	and	_
32-13	5142-5150	FTND/CPD	_
32-14	5151-5155	were	_
32-15	5156-5162	tested	_
32-16	5163-5168	using	_
32-17	5169-5176	Pearson	_
32-18	5177-5178	’	_
32-19	5179-5180	s	_
32-20	5181-5192	correlation	_
32-21	5193-5201	analyses	_
32-22	5202-5203	.	_

Text=The mean FCS in these regions was regressed against age, IQ and years of education.
33-1	5204-5207	The	_
33-2	5208-5212	mean	_
33-3	5213-5216	FCS	_
33-4	5217-5219	in	_
33-5	5220-5225	these	_
33-6	5226-5233	regions	_
33-7	5234-5237	was	_
33-8	5238-5247	regressed	_
33-9	5248-5255	against	_
33-10	5256-5259	age	_
33-11	5260-5261	,	_
33-12	5262-5264	IQ	_
33-13	5265-5268	and	_
33-14	5269-5274	years	_
33-15	5275-5277	of	_
33-16	5278-5287	education	_
33-17	5288-5289	.	_

Text=One and two way ANOVAs followed by Tukey ’ s t-test for multiple comparisons and frequency analyses (Pearson ’ s χ2-test) were conducted (SPSS 20, IBM, Armonk, New York) to compare demographic and behavioral characteristics among groups.
34-1	5290-5293	One	_
34-2	5294-5297	and	_
34-3	5298-5301	two	_
34-4	5302-5305	way	_
34-5	5306-5312	ANOVAs	_
34-6	5313-5321	followed	_
34-7	5322-5324	by	_
34-8	5325-5330	Tukey	_
34-9	5331-5332	’	_
34-10	5333-5334	s	_
34-11	5335-5341	t-test	_
34-12	5342-5345	for	_
34-13	5346-5354	multiple	_
34-14	5355-5366	comparisons	_
34-15	5367-5370	and	_
34-16	5371-5380	frequency	_
34-17	5381-5389	analyses	_
34-18	5390-5391	(	_
34-19	5392-5399	Pearson	_
34-20	5400-5401	’	_
34-21	5402-5403	s	_
34-22	5404-5411	χ2-test	_
34-23	5412-5413	)	_
34-24	5414-5418	were	_
34-25	5419-5428	conducted	_
34-26	5429-5430	(	_
34-27	5431-5435	SPSS	_
34-28	5436-5438	20	_
34-29	5439-5440	,	_
34-30	5441-5444	IBM	_
34-31	5445-5446	,	_
34-32	5447-5453	Armonk	_
34-33	5454-5455	,	_
34-34	5456-5459	New	_
34-35	5460-5464	York	_
34-36	5465-5466	)	_
34-37	5467-5469	to	_
34-38	5470-5477	compare	_
34-39	5478-5489	demographic	_
34-40	5490-5493	and	_
34-41	5494-5504	behavioral	_
34-42	5505-5520	characteristics	_
34-43	5521-5526	among	_
34-44	5527-5533	groups	_
34-45	5534-5535	.	_

